Precision Medicine Randomized Clinical Trial Comparing Molecular Tumor Board Assisted Care to Usual Care

Purpose

This trial will compare Molecular Tumor Board (MTB) assisted care to usual care for patients who have newly diagnosed histologically or cytologically confirmed stage IIb-IV Non-Small Cell Lung Cancer (NSCLC) and are planning to undergo treatment for their cancer.

Condition

  • Non-Small Cell Lung Cancer

Eligibility

Eligible Ages
Between 18 Years and 120 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Clinically suspected or histologically confirmed stage IIb-IV NSCLC who are planning to undergo treatment - No prior systemic therapies for NSCLC, with the exception of adjuvant therapy for early stage NSCLC. Prior surgery and/or radiation is allowed. - Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria

  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with targeted therapy, in the opinion of the treating physician. - Pregnancy

Study Design

Phase
N/A
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Other
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
No Intervention
Usual care recipients
Experimental
Molecular tumor board intervention
  • Other: Molecular tumor board assisted care
    Participants in this group will obtain recommendations for care from the molecular tumor board.

Recruiting Locations

UK Center for Clinical and Translational Science and nearby locations

University of Kentucky
Lexington, Kentucky 40506
Contact:
Timothy Mullett, MD

More Details

NCT ID
NCT05254795
Status
Recruiting
Sponsor
Timothy Mullett

Study Contact

Timothy Mullett, MD
8592186647
timothy.mullett@uky.edu